Vall d'Hebron Institute of Oncology (VHIO)
Alejandro Piris Giménez has extensive work experience in the scientific research field. Alejandro began their career as a Postdoctoral researcher at the Centro Nacional de Biotecnología in 2005 and worked there until 2007. Alejandro then joined Mensor as a Senior consultant from 2007 to 2008. Following that, they transitioned to TCD Pharma as a Research Finance Project Manager from 2008 to 2010. Currently, they hold the role of Scientific Research Manager at the Vall d'Hebron Institute of Oncology (VHIO), a position they have held since 2010. In addition, they have recently been appointed as the Chief Scientific Officer at VHIO.
Alejandro Piris Giménez completed their PhD in Microbiology & Immunology at Institut Pasteur from 2001 to 2005. Alejandro also studied Veterinary Medicine at Universidad Complutense de Madrid, although the start and end years are not specified. Additionally, they had some educational experience at Instituto de Salud Carlos III, but the degree and field of study are unknown.
This person is not in any offices
Vall d'Hebron Institute of Oncology (VHIO)
Under the leadership of Josep Tabernero, the Vall d’Hebron Institute of Oncology (VHIO) has established itself as a cancer research center of proven excellence internationally. It is thanks to Josep's directorship and VHIO's optimal organizational structure based on a purely multidisciplinary and translational model that VHIO talents continue to anticipate and tackle the many unresolved questions in combatting this multifaceted and heterogeneous disease. Located within the Vall d´Hebron Barcelona Hospital Campus, our researchers closely collaborate and interact with Vall d´Hebron University Hospital physician-scientists. Translational science and clinical research are therefore tightly connected which promotes superb interaction and teamwork which, in turn, accelerates the bench-bedside-bed cycle of knowledge. This privileged environment affords VHIO direct access to patients as well as the entire spectrum of oncology professionals who care for them, and a second-to-none appreciation of how cancer science can translate into more powerful, targeted treatments and better practice for the care of patients. VHIO's pioneering model and programs, coupled with its belief in combining strengths through cross-border collaborations, continue to spur advances in reversing cancer resistance, halting metastatic spread and more effectively treating even the most undruggable tumour types. VHIO's translation toward precision oncology.